Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Taiyo Holds Meetings with Clients on GMP Compliance Measures
January 3, 2011
- ARBs Effective for Improving Albuminuria: DSP survey
January 3, 2011
- DSP Completes Merger of Chinese Subsidiaries
January 3, 2011
- US Generics Market to Outgrow New Drugs Market: IGPA Annual Conference
January 3, 2011
- Pfizer Applies for Solu-Medrol Based on Data from the Public Domain
January 3, 2011
- Shionogi, Wakamoto to Copromote Non-prescription Oral Care Products
January 3, 2011
- Apollo Medical to Expand Overseas Training Program for Its Employees
January 3, 2011
- FDA Recommends Withdrawal of Approval for Breast Cancer for Avastin
January 3, 2011
- EPS Acquires SMO in Taiwan
January 3, 2011
- Ain Pharmaciez to Accelerate Development of Medical Malls
December 20, 2010
- Kyowa Kirin Announces Positive Japanese PII Results on KW-0761
December 20, 2010
- 2-Week Limit on Prescription Period Lifted for ARB/CCB Combination Drugs
December 20, 2010
- Astellas Enters into Strategic Equity Deal with Cytori
December 20, 2010
- Favorable Results for KW-0761 Also in US PI/PII Trial
December 20, 2010
- JMA Calls on Korosho to Reconsider Permission of Long-Term Prescriptions
December 20, 2010
- Kyowa Kirin Terminates License Agreement with LivTech for LIV-1205
December 20, 2010
- Favorable Long-Term PIII Results Published for Collategene: AnGes MG
December 20, 2010
- Revolade Benefits Patients with Intractable ITP: Prof. Ikeda
December 20, 2010
- Daiichi Sankyo Subsidiary Luitpold Acquires ROXRO PHARMA
December 20, 2010
- Daiichi Sankyo Completes Enrollment for Edoxaban PIII Trial
December 20, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…